Go Back   Science Forums Biology Forum Molecular Biology Forum Physics Chemistry Forum > General Science Forums > Biology Forum
Register Search Today's Posts Mark Forums Read

Biology Forum Biology Forums. Ask questions and discuss the study of Biology. If you have Biology questions from your homework ask them here!


AREG in tumor biological research on the treatment progress

AREG in tumor biological research on the treatment progress - Biology Forum

AREG in tumor biological research on the treatment progress - Biology Forums. Ask questions and discuss the study of Biology. If you have Biology questions from your homework ask them here!


Reply
 
LinkBack Thread Tools Display Modes
  #1  
Old 06-07-2012, 07:20 AM
UnSubscribed Vendor Advertiser
Points: 466, Level: 9 Points: 466, Level: 9 Points: 466, Level: 9
Activity: 0% Activity: 0% Activity: 0%
 
Join Date: May 2012
Posts: 40
Thanks: 1
Thanked 0 Times in 0 Posts
Default AREG in tumor biological research on the treatment progress



AREG in tumor biological research on the treatment progress
AREG gene positioning in 7p132q22 district, the total length of 200 kb, 28 exons, encodes a protein precursor contains 1210 amino acid residues of AREG; 24 amino acid signal peptide in the post-translational processing hydrolysis, the formation of [Only registered users see links. ] containing 186 amino acid residues of the mature. AREG is a relative molecular mass of 170 000 of the protein tyrosine kinase receptor, composed of three parts: (1) the extracellular domain of N-terminal 621 amino acid residues constitute the ligand binding domain; (2) fixed transmembrane domains, 23 amino acid residues constitute a hydrophobic region of the spiral structure and its receptor in the cell membrane; (3) intracellular domain of 542 amino acid residues constitute further divided into three sub-district: near membrane sub-region, the tyrosine kinase sub-region, the carboxy-terminal sub-district. Found so far, a total of six kinds of ligands of AREG, epidermal growth factor (AREG growth factor, EGF), transforming growth factor α (transforming growth factorα, TGFα), amphiregulin (amphireguin, AR), β 2 cytokines (beta2 celluin, the BTC ), heparin-binding epidermal growth factor (heparin2 bind2ingEGF, HBEGF), epidermal pigment (epiregulin, EPR), the most important of EGF and of TGFα. The combination of AREG and its ligand with high affinity, saturable and specific characteristics.
Combination of AREG and its ligands, form a homodimer with each other, can also form heterodimers with other tyrosine kinase receptors, leading to activation of intracellular tyrosine kinase domain, each other, other cheese acid residues phosphorylated, initiating a series of a cascade of signals to the nucleus, eventually lead to a series of gene activation, leading to tumor cell proliferation, inhibition of apoptosis, promote tumor cell metastasis and lead to the release, chemotherapy tolerance play an important role in the tumorigenesis process.
The dominant negative treatment is the use of genetic engineering techniques to obtain a specific receptor dominant negative mutant (dominant negativemutant), so that highly expressed by high expression of the mutant dominant negative effect arising from a negative regulator of effect . Exogenous dominant negative AREG (AREG2 DNR) combined with AREG ligand and AREG competition, due to the intracellular AREG2DNR missing, no signal transduction function, so as to achieve the role of inhibition of AREG function. AREG2DNR can inhibit the growth of pancreatic cancer cells and increase the sensitivity of pancreatic cancer cells to cisplatin. Chan et al. Construction, expression AREG2DNR the retroviral vector transfected rat poorly differentiated epithelial ovarian cancer NuTu219 cell lines and found the expression AREG2DNR growth capacity of cells parked NuTu219 was significantly inhibited, lost in immunocompetent rats tumorigenic potential model; the with NuTu219 cell lines resistant to cisplatin-resistant cell lines, a retroviral vector expression in transfected AREG2DNR, The resistance was partially reversed.
Reply With Quote
Reply

Tags
areg , biological , progress , research , treatment , tumor


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On

Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Human Cytome Project - Update 24 Jan. 2005 Peter Van Osta Cell Biology and Cell Culture 1 08-01-2010 02:18 PM
Human Cytome Project - an idea - Update 19 April 2005 Peter Van Osta Cell Biology and Cell Culture 1 06-01-2009 02:17 PM
A Human Cytome Project - an idea - Update 14 March 2005 Peter Van Osta Cell Biology and Cell Culture 0 03-14-2005 02:27 PM
Human Cytome Project - Update 6 Jan. 2005 Peter Van Osta Cell Biology and Cell Culture 0 01-06-2005 11:18 AM
Tissue Engineering & Stem Cell Research 2005 Andrew Oliver Protocols and Methods Forum 0 12-02-2004 11:38 PM


All times are GMT. The time now is 09:31 AM.


Powered by vBulletin® Version 3.8.4
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
Copyright 2005 - 2012 Molecular Station | All Rights Reserved
Page generated in 0.17066 seconds with 16 queries